A higher CNV burden and attenuated anti-tumor immune activity, reflected by lower cytolytic activity scores, fewer neoantigens, and mRNA-level downregulation of immunomodulators such as HAVCR2 and LAG3, have been linked to early-onset OTSCC [20,21]. This evidence concerns the gene HAVCR2 and neoplasm.